Management Bios

Jeff Morhet, Chairman, Chief Executive Officer and President

Mr. Morhet's vast experience in the pharmaceutical/biotechnology industry includes positions at Baxter Healthcare, Merck and AstraZeneca. His experience with pharmaceutical product development, manufacturing, regulatory affairs, product commercialization and working with the FDA for both drug and device applications, is extensive. Multiple times Mr. Morhet has been the corporate sponsor to the FDA for programs under development and has had a focus on cellular and intra-cellular anti-cancer drug development.   Prior to InNexus he served as Vice President and General Manager of a NASDAQ-traded pharmaceutical company and refocused their long running cancer research, clinical development and pharmaceutical manufacturing programs.   Mr. Morhet has launched multiple companies, including founding and growing Zila Biotechnology, Inc., a comprehensive research, development and licensing business. He is highly experienced in the areas of investor relations and corporate finance and has participated in raising over $100 Million in public offerings, venture capital, equities and mergers. Mr. Morhet also founded the life science organization THIRDBIOTECH (www.thirdbiotech.com); ThirdBiotech Research Group, a non-profit organization whose mission is to promote the development of science, technology and intellectual property to drive the formation, advancement and growth of biotech companies. The organization includes 3 distinct organizations:

ThirdBiotech Incubator, a novel incubator business model combining contributed resources (Virtual Incubator) and dedicated resources and experts of a biotech competency center.

ThirdBiotech's Molecular Engineering Research Institute (MERI) core facilities dedicated to advancing research in the area of molecular and protein development, a key area of focus for the greater pharmaceutical industry.

Biotech Beacon a novel team of experts who translate, evaluate and profile risk and value of early stage technology and research and provide a value profile for VC investors and third parties.

He is a graduate of Stephen F. Austin State University and attended the Executive MBA program at Arizona State University and other programs from Harvard Business School.

Wade Brooksby, Chief Financial Officer

Mr. Brooksby has held Senior Management positions in various companies ranging in size from small closely held companies to multi-billion dollar Fortune 100 NYSE firms. Mr. Brooksby has been involved in the development of licensing agreements of products and services in the USA, Canada, Mexico, Australia, South Africa, England, Germany, France, Spain and the Netherlands. For the past two years, Mr. Brooksby has been the CFO for a NASDAQ utility energy company. Previously he led the redesign, supervision and implementation of equipment, labor, customer relations and product development of a manufacturing plant for a NASDAQ pharmaceutical company. He has also been involved in the corporate governance for audit, compensation and executive committees for other public companies. Mr. Brooksby has served as an energy-marketing advisor to the Governor of Kentucky and on the Board of Directors of nine public and private companies and two not-for-profit organizations. He completed both his undergraduate and graduate studies in Accounting, Finance and Business Administration at Brigham Young University, located in Provo, Utah.

Thomas Kindt, Ph.D. , Chief Scientific Officer

Thomas Kindt, Ph.D. was most recently Director of Intramural Research, NIAID, NIH, Bethesda, MD and Chief of Laboratory of Immunogenetics, NIAID, NIH and spent a year as Visiting Scientist, Analytical Immunochemistry Laboratory at the Institute Pasteur, Paris. Prior this he was with the Rockefeller University in New York and the City of Hope National Medical Center in Duarte, CA. Dr. Kindt has served on Advisory Boards and Committees of the Institute Pasteur, Tunis, Tunisia; Hematech LLC, Massachusetts; Institute for Medical Sciences, University of Tokyo; REDI Center, Singapore; NIH Facilities Working Group and Blue Ribbon Panel on Bioterrorism and implications for biomedical research. He has authored and co-authored 225 publications, two books and three patents; currently he is an active biomedical consultant, immunology textbook author and adjunct professor at the University of New Mexico’s Department of Biology.

Jur Strobos, M.D., Chief Medical Officer

Dr. Jur Strobos brings with him extensive experience as Director of Policy Research in the office of the Commissioner of the Food and Drug Administration (FDA) and a diverse background in drug law, medical product development, and health care. Most recently, he was Vice President of Clinical Research and Regulatory Affairs for Medicis Pharmaceutical Corporation (NYSE: MRX). His prior medical background and four years of residency training in general surgery training enabled him to engage in policy development across the broad array of FDA activities from foods, devices, drugs, to biological products. His areas of expertise include food and drug law, clinical study design and good manufacturing practices. He has been the successful steward of multiple drugs and devices through the FDA and will be working closely with Dr. Thomas Kindt, InNexus' Chief Scientific Officer and previous Director of Intramural Research at the National Institute of Health.

After law school, a federal court clerkship, and an associate position at a large national law firm, Dr. Strobos received his appointment to the FDA where he worked closely with FDA Commissioner Kessler on regulatory policies. He gained significant experience in regulatory affairs and then served as Clinical Program Development and Regulatory Consultant for Greenberg Traurig, LLP, and Olson, Frank & Weeda, PC, in Washington, DC. He also served as Vice President of Clinical Research and Regulatory Affairs for R&D Laboratories, Inc. Dr. Strobos received his medical training at the University of Chicago, his legal training at the University of Pennsylvania and is admitted to practice in both Washington, DC and California. He has numerous publications and awards including the PHS Special Recognition Award, the FDA Award of Merit and two Commissioner Special Citations.

J. Donald Capra, MD., Scientific Advisory Board Chairman

Dr. Capra serves as President Emeritus of the Oklahoma Medical Research Foundation (OMRF). For nine years (1997-2006) Dr. Capra served OMRF as President and oversaw an impressive period of growth and new scientific discovery including significant increases in external research funding, scientific faculty and facility improvements. In addition to his current duties as President Emeritus, he continues his research projects in the laboratory as Member and Head of the Molecular Immunogenetics Research Program at OMRF. Prior to OMRF, he served as professor of microbiology and internal medicine and was the Edwin L. Cox Distinguished Chair in Immunology and Genetics of University of Texas Southwestern Medical Center and Director of Southwestern’s Molecular Immunology Center. Dr. Capra is also well known for his studies of antibody genes and how they are mutated in autoimmune disorders and was an early leader in the field of monoclonal antibodies. Early in his career he was instrumental in defining the association of immunoglobulin hypervariable regions with the antibody combining site. More recently he has made contributions to our understanding of human B cell development. Along the way he has been a major contributor to our understanding of the various mechanisms of antibody diversity.